Works matching IS 11753277 AND DT 2025 AND VI 25 AND IP 1
Results: 14
Bempedoic Acid: A Review in Cardiovascular Risk Reduction in Statin-Intolerant Patients: Bempedoic Acid: A Review: A. McGuigan, H. A. Blair.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 7, doi. 10.1007/s40256-024-00714-9
- By:
- Publication type:
- Article
Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect": Author's Reply to Peronard and Mayntz: D. Aristizábal-Colorado et al.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Comment on "SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect": Comment on "SGLT2 Inhibitors: R. Peronard and S. Mayntz.
- Published in:
- 2025
- By:
- Publication type:
- Letter to the Editor
Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis: Cardiovascular Safety of Patisiran: V. Jaiswal et al.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial Hypertension: Sotatercept in PAH: J. Villanueva et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 17, doi. 10.1007/s40256-024-00694-w
- By:
- Publication type:
- Article
Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials: Efficacy of Colchicine for Prevention of Stroke and Adverse CV Events: A Meta-analysis of RCTs: V. Jaiswal et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 83, doi. 10.1007/s40256-024-00689-7
- By:
- Publication type:
- Article
Vitamin D–Parathyroid Hormone–Fibroblast Growth Factor 23 Axis and Cardiac Remodeling: Vitamin D–Parathyroid Hormone–FGF23 Axis and Cardiac Remodeling: C. Deng et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 25, doi. 10.1007/s40256-024-00688-8
- By:
- Publication type:
- Article
Cardiomodulatory Effects of Cardiometabolic and Antihyperglycemic Medications: The Roles of Oxidative and Endoplasmic Reticulum Stress: Cardioprotective Effects of Antihyperglycemic Medications: A. D. Mooradian.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 37, doi. 10.1007/s40256-024-00685-x
- By:
- Publication type:
- Article
Efficacy of Chronic Use of Sodium–Glucose Co-transporter 2 Inhibitors on the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Type 2 Diabetes Mellitus Following Coronary Procedures: A Systematic Review and Meta-Analysis: SGLT2 Inhibitors and Contrast-Induced AKI: K. Dimitriadis et al
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 57, doi. 10.1007/s40256-024-00684-y
- By:
- Publication type:
- Article
Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Meta-analysis: PCSK9 Inhibitors in Heterozygous FH: M. Movahedan et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 47, doi. 10.1007/s40256-024-00682-0
- By:
- Publication type:
- Article
Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: SGLT2i Post-AMI: N. H. Y. Lin et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 71, doi. 10.1007/s40256-024-00680-2
- By:
- Publication type:
- Article
Long-Term Effects of Low-Dose Aspirin on Gastrointestinal Symptoms and Bleeding Complications in Patients with Type 2 Diabetes: Long-Term Effects of Low-Dose Aspirin on Gastrointestinal Symptoms and Bleeding: N. Masutani et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 95, doi. 10.1007/s40256-024-00679-9
- By:
- Publication type:
- Article
The Influence of High Body Mass Index (BMI > 35 kg/m<sup>2</sup>) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation: BMI ≥ 35 kg/m<sup>2</sup> Impact on Apixaban Levels in Atrial Fibrillation Patients: M. Hilu et al.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 113, doi. 10.1007/s40256-024-00678-w
- By:
- Publication type:
- Article
Flurpiridaz F 18: First Approval: Flurpiridaz F 18: First Approval: S. J. Keam.
- Published in:
- American Journal of Cardiovascular Drugs, 2025, v. 25, n. 1, p. 1, doi. 10.1007/s40256-024-00718-5
- By:
- Publication type:
- Article